Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study
Authors:
- 18 October 2008
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 91 (3) , 299-305
Abstract
Background A systemic and intraventricular polychemotherapy regimen (the Bonn protocol) without radiotherapy resulted in durable responses in 75% of patients Patients and methods From August 2003 to November 2005, 18 patients with PCNSL Results Study accrual was prematurely stopped in November 2005 due to a high rate of early relapses. Seventeen of 18 patients were assessable for response: nine (53%) achieved complete response (CR), two (12%) complete response/unconfirmed (CRu) and two (12%) partial response (PR); four (24%) showed progressive disease (PD). One treatment was stopped due to toxicity. Median follow-up was 23 months, median response duration was only 10 months in responding patients, and median time to treatment failure (TTF) was 8 months in the whole group. Median overall survival (OS) has not been reached. Systemic toxicity was mainly hematologic. Conclusions In PCNSL patients <60 years, polychemotherapy without intraventricular treatment results in a high response rate, but is associated with early relapses in the majority of cases. This is in contrast to the results achieved with the same protocol but with intraventricular treatment.Keywords
This publication has 28 references indexed in Scilit:
- Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic ModelJournal of Clinical Oncology, 2006
- Primary CNS LymphomaJournal of Clinical Oncology, 2006
- Combined-modality therapy for primary central nervous system lymphoma: Long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Neuro-oncology update: 2005Current Opinion in Neurology, 2005
- Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS LymphomaJournal of Clinical Oncology, 2005
- NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma: Final reportAnnals of Neurology, 2005
- Neuropsychological outcome after chemotherapy for primary CNS lymphomaNeurology, 2005
- High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non–AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962Journal of Clinical Oncology, 2003
- Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred RadiotherapyJournal of Clinical Oncology, 2003
- Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor GroupJournal of Clinical Oncology, 2003